G. M. Clifford, J. S. Smith, M. Plummer, N. Muñoz, and S. Franceschi, Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis, Br J Cancer. janv, vol.88, issue.1, pp.63-73, 2003.

, IARC monographs on the evaluation of carcinogenic risks to humans

, International Agency for Research on Cancer, Cancer Epidemiology and Prevention. Fourth Edition, vol.100, 1328.

H. Autorité-de-santé, Évaluation de la recherche des papillomavirus humains (HPV) en dépistage primaire des lésions précancéreuses et cancéreuses du col de l'utérus et de la place du double immuno-marquage p16/Ki67

D. Sur,

G. Ronco, J. Dillner, K. M. Elfström, S. Tunesi, P. Snijders et al., Efficacy of HPVbased screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials, The Lancet. févr, vol.383, issue.9916, pp.524-556, 2014.

, Cervic cancer screening: [IARC Working Group on the Evaluation on Cancer-Preventive Strategies which met in, pp.20-27, 2004.

D. Gautier, L. Guyader-peyrou, U. Sandra, G. Zoé, C. Pascale et al., Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018 -Tumeurs solides

F. Santé-publique, Bull Épidémiologique Hebd, pp.424-454, 2018.

F. X. Bosch, C. Robles, M. Díaz, M. Arbyn, I. Baussano et al., HPV-FASTER: broadening the scope for prevention of HPV-related cancer, Nat Rev Clin Oncol. févr, vol.13, issue.2, pp.119-151, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02451776

S. Vaccarella, M. Laversanne, J. Ferlay, and F. Bray, Cervical cancer in Africa, Latin America and the Caribbean and Asia: Regional inequalities and changing trends: Cervical cancer in Africa, Latin America and the Caribbean and Asia, Int J Cancer, vol.141, issue.10, pp.1997-2001, 2017.

F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 2018.

D. Forman, C. De-martel, C. J. Lacey, I. Soerjomataram, J. Lortet-tieulent et al., Global Burden of Human Papillomavirus and Related Diseases. Vaccine, vol.30, pp.12-23, 2012.

C. De-martel, M. Plummer, J. Vignat, and S. Franceschi, Worldwide burden of cancer attributable to HPV by site, country and HPV type: Worldwide burden of cancer attributable to HPV, Int J Cancer. 15 août, vol.141, issue.4, pp.664-70, 2017.

J. W. Sellors and R. S. , Colposcopie et Traitement des Néoplasies Cervicales Intraépithéliales : Manuel à l'usage des débutants, 2003.

D. Sur,

H. Bernard, R. D. Burk, Z. Chen, K. Van-doorslaer, H. Hausen et al., Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments, Virology. mai, vol.401, issue.1, pp.70-79, 2010.

E. De-villiers, Cross-roads in the classification of papillomaviruses, Virology, vol.445, issue.1-2, pp.2-10, 2013.

E. De-villiers, C. Fauquet, T. R. Broker, H. Bernard, and . Zur-hausen, Classification of papillomaviruses, Virology. juin, vol.324, issue.1, pp.17-27, 2004.

N. Muñoz, F. X. Bosch, S. De-sanjosé, R. Herrero, X. Castellsagué et al., Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer, N Engl J Med. 6 févr, vol.348, pp.518-545, 2003.

J. Doorbar, W. Quint, L. Banks, I. G. Bravo, M. Stoler et al., The Biology and Life-Cycle of Human Papillomaviruses. Vaccine, vol.30, pp.55-70, 2012.

S. Hantz, A. S. Denis, and F. , Vaccins prophylactiques antipapillomavirus : enjeux et perspectives, Gynécologie Obstétrique Fertil. juill, vol.34, issue.7-8, pp.647-55, 2006.

D. Riethmuller, J. P. Schaal, and C. Mougin, Épidémiologie et histoire naturelle de l'infection génitale à papillomavirus humain, Gynécologie Obstétrique Fertil. févr, vol.30, issue.2, pp.139-185, 2002.

E. F. Dunne, C. M. Nielson, K. M. Stone, L. E. Markowitz, and A. R. Giuliano, Prevalence of HPV Infection among Men: A Systematic Review of the Literature, J Infect Dis, vol.194, issue.8, pp.1044-57, 2006.

L. E. Manhart and L. A. Koutsky, Do Condoms Prevent Genital HPV Infection, External Genital Warts, or Cervical Neoplasia?: A Meta-Analysis, Sex Transm Dis, vol.29, issue.11, p.725, 2002.

G. Clifford, S. Franceschi, M. Diaz, N. Muñoz, and L. L. Villa, Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases, Vaccine. août, vol.24, pp.26-34, 2006.

R. B. Roden, D. R. Lowy, and J. T. Schiller, Papillomavirus is resistant to desiccation, J Infect Dis, vol.176, issue.4, pp.1076-1085, 1997.

J. Cason and C. A. Mant, High-risk mucosal human papillomavirus infections during infancy & childhood, J Clin Virol. mars, vol.32, pp.52-60, 2005.

S. De-sanjosé, M. Brotons, and M. A. Pavón, The natural history of human papillomavirus infection, Best Pract Res Clin Obstet Gynaecol. févr, vol.47, pp.2-13, 2018.

V. Laniosz, S. A. Dabydeen, M. A. Havens, and P. I. Meneses, Human Papillomavirus Type 16 Infection of Human Keratinocytes Requires Clathrin and Caveolin-1 and Is Brefeldin A Sensitive, J Virol. 15 août, vol.83, issue.16, pp.8221-8253, 2009.

J. Monsonego, Traité des infections et pathologies génitales à papillomavirus, vol.506, 2008.

. Bégué, Les vaccins des papillomavirus humains, vol.125, 2009.

E. J. Crosbie, M. H. Einstein, S. Franceschi, and H. C. Kitchener, Human papillomavirus and cervical cancer, The Lancet. sept, vol.382, issue.9895, pp.889-99, 2013.

P. Snijders, C. Hogewoning, A. T. Hesselink, J. Berkhof, F. J. Voorhorst et al., Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology, Int J Cancer. 1 sept, vol.119, issue.5, pp.1102-1109, 2006.

M. Disponible-sur-;-schiffman, J. Doorbar, N. Wentzensen, S. De-sanjosé, C. Fakhry et al., Carcinogenic human papillomavirus infection, :16086. 36. Nayar R, Wilbur DC. The bethesda system for reporting cervical cytology: Definitions, criteria, and explanatory notes, vol.2, 2015.

D. Sur,

H. Autorité-de-santé, Conduite à tenir devant une patiente ayant un frottis cervico-utérin anormal, 2002.

D. Sur,

F. Santé-publique, Vers la généralisation du dépistage organisé du cancer du col de l'utérus, 2017.

T. Shoji, E. Takatori, S. Takeuchi, A. Yoshizaki, N. Uesugi et al., Clinical significance of atypical glandular cells in the Bethesda system 2001: a comparison with the histopathological diagnosis of surgically resected specimens, Cancer Invest. mai, vol.32, issue.4, pp.105-114, 2014.

F. Denis, S. Hanz, and A. S. Clairance, persistance et récidive de l'infection à Papillomavirus

, Gynécologie Obstétrique Fertil. avr, vol.36, issue.4, pp.430-470, 2008.

J. Baldauf, G. Averous, E. Baulon, V. Thoma, A. Talha-vautravers et al., Néoplasies intraépithéliales du col. EMC -Gynécologie. avr, vol.8, issue.2, pp.1-21, 2013.

S. Hantz, A. S. Denis, and F. , Vaccination anti-papillomavirus, Gastroentérologie Clin Biol. mai, vol.32, issue.5, pp.221-251, 2008.

A. G. Ostör, Natural history of cervical intraepithelial neoplasia: a critical review, Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. avr, vol.12, issue.2, pp.186-92, 1993.

S. De-sanjose, W. G. Quint, L. Alemany, D. T. Geraets, J. E. Klaustermeier et al., Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study, Lancet Oncol, vol.11, issue.11, pp.1048-56, 2010.

M. Schmitt, C. Depuydt, I. Benoy, J. Bogers, J. Antoine et al., Viral Load of High-Risk Human Papillomaviruses as Reliable Clinical Predictor for the Presence of Cervical Lesions, Cancer Epidemiol Prev Biomark. 1 mars, vol.22, issue.3, pp.406-420, 2013.

A. T. Lorincz, P. E. Castle, M. E. Sherman, D. R. Scott, A. G. Glass et al., Is Human Papillomavirus Viral Load a Clinically Useful Predictive Marker? A Longitudinal Study, Cancer Epidemiol Prev Biomark. 1 mars, vol.360, issue.9328, pp.832-839, 2002.

L. F. Xi, J. P. Hughes, P. E. Castle, Z. R. Edelstein, C. Wang et al., Viral Load in the Natural History of Human Papillomavirus Type 16 Infection: A Nested Case-control Study, J Infect Dis. 15 mai, vol.203, issue.10, pp.1425-1458, 2011.

C. E. Depuydt, J. Jonckheere, M. Berth, G. M. Salembier, A. J. Vereecken et al., Serial typespecific human papillomavirus (HPV) load measurement allows differentiation between regressing cervical lesions and serial virion productive transient infections, Cancer Med. août, vol.4, issue.8, pp.1294-302, 2015.

. Duin-m-van, P. Snijders, H. Schrijnemakers, and F. J. Voorhorst,

. Mae, Human papillomavirus 16 load in normal and abnormal cervical scrapes: An indicator of CIN II/III and viral clearance, Int J Cancer, vol.98, issue.4, pp.590-595, 2002.

M. Schmitt, C. Depuydt, I. Benoy, J. Bogers, J. Antoine et al., Multiple Human Papillomavirus Infections with High Viral Loads Are Associated with Cervical Lesions but Do Not Differentiate Grades of Cervical Abnormalities, J Clin Microbiol. 1 mai, vol.51, issue.5, pp.1458-64, 2013.

B. D. Bello, A. Spinillo, P. Alberizzi, S. Cesari, B. Gardella et al., Cervical infections by multiple human papillomavirus (HPV) genotypes: Prevalence and impact on the risk of precancerous epithelial lesions, J Med Virol. avr, vol.81, issue.4, pp.703-715, 2009.

H. Trottier, M. S. Costa, M. C. Sobrinho, J. P. Duarte-franco, E. Rohan et al., Human Papillomavirus Infections with Multiple Types and Risk of Cervical Neoplasia, Cancer Epidemiol Prev Biomark. 1 juill, vol.15, issue.7, pp.1274-80, 2006.

D. Maucort-boulch, M. Plummer, P. E. Castle, F. Demuth, M. Safaeian et al., Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology, Int J Cancer. 1 févr, vol.126, issue.3, pp.684-91, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00539307

J. P. Shepherd, G. K. Frampton, and P. Harris, Interventions for encouraging sexual behaviours intended to prevent cervical cancer. Cochrane Database Syst Rev, vol.13

R. Disponible-sur-;-karlsson, M. Jonsson, K. Edlund, M. Evander, A. Gustavsson et al., Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study, Sex Transm Dis. avr, vol.22, issue.2, pp.119-146, 1995.

C. Ley, H. M. Bauer, A. Reingold, M. H. Schiffman, J. C. Chambers et al., Determinants of genital human papillomavirus infection in young women, J Natl Cancer Inst. 17 juill, vol.83, issue.14, pp.997-1003, 1991.

N. Muñoz, I. Kato, F. X. Bosch, J. Eluf-neto, D. Sanjosé et al., Risk factors for HPV DNA detection in middle-aged women, Sex Transm Dis. déc, vol.23, issue.6, pp.504-514, 1996.

X. Castellsagué, F. X. Bosch, N. Muñoz, C. Meijer, K. V. Shah et al., Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners, N Engl J Med. 11 avr, vol.346, issue.15, pp.1105-1117, 2002.

X. Castellsagué, F. X. Bosch, and N. Muñoz, Environmental co-factors in HPV carcinogenesis, Virus Res, vol.89, issue.2, pp.191-200, 2002.

N. Muñoz, S. Franceschi, C. Bosetti, V. Moreno, R. Herrero et al., Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study, The Lancet. mars, vol.359, issue.9312, pp.1093-101, 2002.

P. Autier, M. Coibion, F. Huet, and A. Grivegnee, Transformation zone location and intraepithelial neoplasia of the cervix uteri, Br J Cancer. août, vol.74, issue.3, pp.488-90, 1996.

S. Sethi, M. Müller, A. Schneider, M. Blettner, E. Smith et al., Serologic response to the E4, E6, and E7 proteins of human papillomavirus type 16 in pregnant women, Am J Obstet Gynecol. févr, vol.178, issue.2, pp.360-364, 1998.

L. A. Denny, S. Franceschi, S. De-sanjosé, I. Heard, A. B. Moscicki et al., Human Papillomavirus, Human Immunodeficiency Virus and Immunosuppression. Vaccine, vol.30, pp.168-74, 2012.

X. Sun and T. J. Bush, Human Papillomavirus Infection in Women Infected with the Human Immunodeficiency Virus, N Engl J Med, vol.7, 1997.

I. Heard, H. Cubie, D. Mesher, and P. Sasieni, for the MACH-1 Study Group. Characteristics of HPV infection over time in European women who are HIV-1 positive: HPV infection in HIV, BJOG Int J Obstet Gynaecol. janv, vol.120, issue.1, pp.41-50, 2013.

T. Freeman-wang and P. Walker, Colposcopy in special circumstances: Pregnancy, immunocompromise, including HIV and transplants, adolescence and menopause, Best Pract Res Clin Obstet Gynaecol, vol.25, issue.5, pp.653-65, 2011.

D. Vuyst, H. Lillo, F. Broutet, N. Smith, and J. S. , HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy, Eur J Cancer Prev, vol.17, issue.6, pp.545-54, 2008.

D. R. Tate and R. J. Anderson, Recrudescence of cervical dysplasia among women who are infected with the human immunodeficiency virus: A case-control analysis, Am J Obstet Gynecol. mai, vol.186, issue.5, pp.880-882, 2002.

, CDC. CDC Works, vol.24, issue.7, 2019.

D. Sur,

M. Veroux, D. Corona, G. Scalia, V. Garozzo, M. Gagliano et al., Surveillance of Human Papilloma Virus Infection and Cervical Cancer in Kidney Transplant Recipients: Preliminary Data, Transplant Proc. mai, vol.41, issue.4, pp.1191-1195, 2009.

M. R. Brown, A. Noffsinger, M. R. First, P. I. Husseinzadeh, and N. Hpv-subtype, Analysis

, Lower Genital Tract Neoplasms of Female Renal Transplant Recipients, Gynecol Oncol, vol.79, issue.2, pp.220-224, 2000.

A. Raposo, C. Tani, J. Costa, and M. Mosca, Human papillomavirus infection and cervical lesions in rheumatic diseases: a systematic review, Acta Reumatol Port. sept, vol.41, issue.3, pp.184-90, 2016.

M. M. Madeleine, B. Brumback, K. L. Cushing-haugen, S. M. Schwartz, J. R. Daling et al., Human Leukocyte Antigen Class II and Cervical Cancer Risk: A Population-Based Study, J Infect Dis. déc, vol.186, issue.11, pp.1565-74, 2002.

M. Ghaderi, K. Wallin, F. Wiklund, L. N. Zake, G. Hallmans et al., Tobacco smoke and involuntary smoking: this publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, Int J Cancer, vol.100, issue.6, pp.11-18, 2002.

M. Plummer, R. Herrero, S. Franceschi, C. Meijer, P. Snijders et al., Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control, vol.14, pp.805-819, 2003.

P. Appleby, V. Beral, and A. Berrington-de-gonzález, Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies, Int J Cancer, vol.118, issue.6, pp.1481-95, 2006.

S. Vaccarella, R. Herrero, P. Snijders, M. Dai, J. O. Thomas et al., Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys, Int J Epidemiol. 1 juin, vol.37, issue.3, pp.536-582, 2008.

A. R. Giuliano, R. L. Sedjo, D. J. Roe, R. Harris, S. Baldwin et al., Clearance of Oncogenic Human Papillomavirus (HPV) Infection: Effect of Smoking (United States), Cancer Causes Control, vol.13, issue.9, pp.839-885, 2002.

P. Chan, A. R. Chang, J. Cheung, D. Chan, L. Y. Xu et al., Determinants of Cervical Human Papillomavirus Infection: Differences between High-and Low-Oncogenic Risk Types, J Infect Dis. janv, vol.185, issue.1, pp.28-35, 2002.

S. Tay and K. Tay, Passive cigarette smoking is a risk factor in cervical neoplasia, Gynecol Oncol. avr, vol.93, issue.1, pp.116-136, 2004.

C. M. Dresler, M. E. León, K. Straif, R. Baan, and B. Secretan, Reversal of risk upon quitting smoking. The Lancet, juill, vol.368, issue.9533, pp.348-357, 2006.

E. Roura, X. Castellsagué, M. Pawlita, N. Travier, T. Waterboer et al., Smoking as a major risk factor for cervical cancer and pre-cancer: Results from the EPIC cohort, Int J Cancer, vol.135, issue.2, pp.453-66, 2014.

A. Szarewski, P. Sasieni, R. Edwards, J. Cuzick, M. J. Jarvis et al., Effect of smoking cessation on cervical lesion size. The Lancet, avr, vol.347, issue.9006, pp.941-944, 1996.

W. Poppe, P. S. Ide, M. Drijkoningen, J. M. Lauweryns, A. Van-assche et al., Tobacco Smoking Impairs the Local Immunosurveillance in the Uterine Cervix, Gynecol Obstet Invest, vol.39, issue.1, p.417, 1990.

B. Prokopczyk, J. E. Cox, D. Hoffmann, and S. E. Se, Identification of Tobacco-Specific Carcinogen in the Cervical Mucus of Smokers and Nonsmokers, JNCI J Natl Cancer Inst, vol.89, issue.12, pp.868-73, 1997.

V. Moreno, F. X. Bosch, N. Muñoz, C. J. Meijer, K. V. Shah et al., International Agency for Research on Cancer, International Agency for Research on Cancer, éditeurs. Human papillomaviruses: views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenesis Risks to Humans, which met in Lyon, The Lancet. mars, vol.359, issue.9312, pp.6-13, 1995.

S. Mitrani-rosenbaum, R. Tsvieli, and R. Tur-kaspa, Oestrogen Stimulates Differential Transcription of Human Papillomavirus Type 16 in SiHa Cervical Carcinoma Cells, J Gen Virol. 1 août, vol.70, issue.8, pp.2227-2259, 1989.

G. Naldini, C. Grisci, M. Chiavarini, and R. Fabiani, Association between human papillomavirus and chlamydia trachomatis infection risk in women: a systematic review and meta-analysis, Int J Public Health. juill, vol.64, issue.6, pp.943-55, 2019.

H. Zhu, Z. Shen, H. Luo, W. Zhang, and X. Zhu, Chlamydia Trachomatis Infection-Associated Risk of Cervical Cancer: A Meta-Analysis, Medicine (Baltimore). mars, vol.95, issue.13, p.3077, 2016.

J. Paavonen, Chlamydia trachomatis infections of the female genital tract: State of the art, Ann Med. févr, vol.44, issue.1, pp.18-28, 2012.

J. Silva, F. Cerqueira, and R. Medeiros, Chlamydia trachomatis infection: implications for HPV status and cervical cancer, Arch Gynecol Obstet. avr, vol.289, issue.4, pp.715-738, 2014.

S. Seraceni, D. Seta, F. Colli, C. , D. Savio et al., High prevalence of hpv multiple genotypes in women with persistent chlamydia trachomatis infection, Infect Agent Cancer, vol.9, issue.1, p.30, 2014.

S. Li and X. Wen, Seropositivity to herpes simplex virus type 2, but not type 1 is associated with cervical cancer: NHANES (1999-2014). BMC Cancer, vol.17, 2017.

. Disponible, E. E. Hatch, A. L. Herbst, R. N. Hoover, K. L. Noller et al., Incidence of squamous neoplasia of the cervix and vagina in women exposed prenatally to diethylstilbestrol (United States). Cancer Causes Control, vol.12, pp.837-882, 2001.

R. N. Hoover, M. Hyer, R. M. Pfeiffer, A. E. Bond, B. Cheville et al., Adverse Health Outcomes in Women Exposed In Utero to Diethylstilbestrol, N Engl J Med, vol.365, issue.14, pp.1304-1318, 2011.

J. Verloop, F. E. Leeuwen, . Van, T. Helmerhorst, . Kok-imcm-de et al., Risk of cervical intra-epithelial neoplasia and invasive cancer of the cervix in DES daughters, Gynecol Oncol. 1 févr, vol.144, issue.2, pp.305-316, 2017.

R. Troisi, E. E. Hatch, J. R. Palmer, L. Titus, S. J. Robboy et al., Prenatal diethylstilbestrol exposure and high-grade squamous cell neoplasia of the lower genital tract, Am J Obstet Gynecol. sept, vol.215, issue.3, pp.322-323, 2016.

S. J. Robboy, K. L. Noller, P. O'brien, R. H. Kaufman, D. Townsend et al., Increased Incidence of Cervical and Vaginal Dysplasia in 3,980 Diethylstilbestrol-Exposed Young Women: Experience of the National Collaborative Diethylstilbestrol Adenosis Project, JAMA. 7 déc, vol.252, issue.21, pp.2979-83, 1984.

J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer. 1 mars, vol.136, issue.5, pp.359-86, 2015.

S. J. Newmann and E. O. Garner, Social inequities along the cervical cancer continuum: a structured review, Cancer Causes Control. févr, vol.16, issue.1, pp.63-70, 2005.

E. M. Cheng, P. M. Atkinson, and A. K. Shahani, Elucidating the spatially varying relation between cervical cancer and socio-economic conditions in England, Int J Health Geogr, vol.10, issue.1, p.51, 2011.

H. Inca, Cancers gynécologiques -Recommandations et outils d'aide à la pratique. Conduite à tenir devant une femme ayant une cytologie cervico-utérine anormale, 2016.

D. Sur,

J. E. Tota, J. Bentley, J. Blake, F. Coutlée, M. A. Duggan et al., Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm, Prev Med. mai, vol.98, pp.5-14, 2017.

M. Origoni, . Cristoforoni, . Mariani, . Costa, . Scirpa et al., HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice, 2012.

P. Sasieni, J. Cuzick, and E. Lynch-farmery, Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer, Br J Cancer. avr, vol.73, issue.8, pp.1001-1006, 1996.

X. Carcopino, C. Camus, and P. Halfon, Diagnostic et prise en charge clinique des infections cervicales à HPV, Presse Médicale. juill, vol.44, issue.7-8, pp.716-742, 2015.

H. Autorité-de-santé, État des lieux et recommandations pour le dépistage du cancer du col de l'utérus en France

D. Sur,

P. Basu, A. Ponti, A. Anttila, G. Ronco, C. Senore et al., Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report: Cancer Screening in European Union, Int J Cancer. 1 janv, vol.142, issue.1, pp.44-56, 2018.

, Les 17 objectifs du Plan Cancer, 2014.

D. Sur,

J. Boulanger, J. Gondry, P. Verhoest, . Colposcopie, and . Emc--gynécologie, janv, vol.6, issue.1, pp.1-13, 2011.

C. Quereux, J. Boulanger, J. Bory, and J. Gondry, Dépistage du cancer du col, place de la colposcopie, Le dépistage du cancer du col de l'utérus, pp.139-50, 2005.

M. H. Stoler, M. D. Vichnin, A. Ferenczy, D. G. Ferris, G. Perez et al., The accuracy of colposcopic biopsy: Analyses from the placebo arm of the Gardasil clinical trials, Int J Cancer, vol.128, issue.6, pp.1354-62, 2011.

S. B. Cantor, M. Cárdenas-turanzas, D. D. Cox, E. N. Atkinson, G. M. Nogueras-gonzalez et al., Accuracy of Colposcopy in the Diagnostic Setting Compared With the Screening Setting, Obstet Gynecol. janv, vol.111, issue.1, pp.7-14, 2008.

N. Muñoz, F. X. Bosch, X. Castellsagué, M. Díaz, S. De-sanjose et al., Against which human papillomavirus types shall we vaccinate and screen? the international perspective: HPV Types for Vaccines and Screening Tests, Int J Cancer. 20 août, vol.111, issue.2, pp.278-85, 2004.

J. S. Smith, L. Lindsay, B. Hoots, J. Keys, S. Franceschi et al., Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update, Int J Cancer, vol.121, issue.3, pp.621-653, 2007.

J. B. Robbins, R. Schneerson, and S. C. Szu, Perspective: Hypothesis: Serum IgG Antibody Is Sufficient to Confer Protection against Infectious Diseases by Inactivating the Inoculum, J Infect Dis. 1 juin, vol.171, issue.6, pp.1387-98, 1995.

R. M. Zinkernagel, On Natural And Artificial Vaccinations, Annu Rev Immunol. avr, vol.21, issue.1, pp.515-561, 2003.

M. E. Hagensee, N. Yaegashi, and D. A. Galloway, Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins, J Virol. janv, vol.67, issue.1, pp.315-337, 1993.

J. Brun, Vaccination contre le papillomavirus humain, J Gynécologie Obstétrique Biol Reprod. févr, vol.37, issue.1, pp.155-66, 2008.

R. C. Rose, R. C. Reichman, and W. Bonnez, Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera, J Gen Virol. 1 août, vol.75, issue.8, pp.2075-2084, 1994.

V. Krogh and G. , Anogenital warts (condylomata acuminata), Eur J Dermatol, vol.11, issue.6, pp.598-603, 2001.

S. Giannini, E. Hanon, P. Moris, M. Vanmechelen, S. Morel et al., Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only, Vaccine. 14 août, vol.24, pp.5937-5986, 2006.

, Vaccination contre les infections à papillomavirus humains des jeunes filles de 14 à 23 ans, HCSP, 2010.

D. Sur,

, Infections à HPV des jeunes filles : révision de l'âge de vaccination, HCSP

D. Sur,

, Ministère des affaires sociales et de la santé, 2016.

, Haut Conseil de la Santé Publique, HCSP. Prévention des infections à HPV : place du vaccin Gardasil 9®, 2017.

S. Ministère-des, D. M. De-la-santé, D. M. , and D. M. Le, , 2019.

, Ministère des Solidarités et de la Santé, 2019.

D. Sur,

, Vaccinations des personnes immunodéprimées ou aspléniques

, Haut Conseil de la Santé Publique, HCSP. Recommandations vaccinales contre les infections à papillomavirus humains chez les hommes, 2016.

H. Autorité-de-santé, Vaccination contre les papillomavirus chez les garçons

D. Sur,

S. Ministère-des, L. De, and . Santé, , 2015.

D. Sur,

L. Fonteneau, M. Ragot, I. Parent-du-châtelet, J. Guthmann, and D. Lévy-bruhl, The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety, BMC Public Health. 12 déc, vol.15, issue.1, p.1233, 2015.

F. Santé-publique, La vaccination contre les infections à papillomavirus humains

, Rencontres régionales de santé publique, 2019.

, RESUME DES CARACTERISTIQUES DU PRODUIT Gardasil, 2010.

, RESUME DES CARACTERISTIQUES DU PRODUIT Cervarix, 2010.

M. Arbyn, L. Xu, C. Simoens, and M. Pp, Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev

, Disponible sur, 2018.

E. D. Moreira, S. L. Block, D. Ferris, A. R. Giuliano, O. Iversen et al., Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials, Pediatrics. août, vol.138, issue.2, p.20154387, 2016.

. Ansm, Rapport de la Réunion du Comité technique de Pharmacovigilance -CT012018061, 2018.

S. Miranda, C. Chaignot, C. Collin, R. Dray-spira, A. Weill et al., Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2 million young girls in France, Vaccine. août, vol.35, issue.36, pp.4761-4769, 2017.

N. M. Scheller, H. Svanström, B. Pasternak, L. Arnheim-dahlström, K. Sundström et al.,

, Quadrivalent HPV Vaccination and Risk of Multiple Sclerosis and Other Demyelinating Diseases of the Central Nervous System, JAMA. 6 janv, vol.313, issue.1, p.54, 2015.

A. Meggiolaro, G. Migliara, L. Torre, and G. , Association between Human Papilloma Virus (HPV) vaccination and risk of Multiple Sclerosis: A systematic review. Hum Vaccines Immunother, vol.4, pp.1266-74, 2018.

N. Andrews, J. Stowe, and E. Miller, No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England, Vaccine. mars, vol.35, issue.13, pp.1729-1761, 2017.

J. Gee, L. Sukumaran, and E. Weintraub, Risk of Guillain-Barré Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink. Vaccine, vol.35, pp.5756-5764, 2017.

B. N. Butts, P. R. Fischer, and K. J. Mack, Human Papillomavirus Vaccine and Postural Orthostatic Tachycardia Syndrome: A Review of Current Literature, J Child Neurol, vol.32, issue.11, pp.956-65, 2017.

T. Okuhara, H. Ishikawa, M. Okada, M. Kato, and T. Kiuchi, Newspaper coverage before and after the HPV vaccination crisis began in Japan: a text mining analysis, BMC Public Health. déc, vol.19, issue.1, p.770, 2019.

, Relevé épidémiologique hebdomadaire: Réunion du Comité consultatif mondial pour la sécurité des vaccins, vol.92, pp.393-404, 2017.

, Agence européenne du médicament (EMA), p.40, 2015.

. Ansm, Compte-rendu de la réunion du Comité technique de pharmacovigilance, 2015.

L. Bruni, M. Diaz, L. Barrionuevo-rosas, R. Herrero, F. Bray et al., Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis, Lancet Glob Health. juill, vol.4, issue.7, pp.453-63, 2016.

S. De-sanjose, M. Brotons, D. S. Lamontagne, and L. Bruni, Human papillomavirus vaccine disease impact beyond expectations, Curr Opin Virol. déc, vol.39, pp.16-22, 2019.

M. T. Hall, K. T. Simms, J. Lew, M. A. Smith, J. M. Brotherton et al., The projected timeframe until cervical cancer elimination in Australia: a modelling study, Lancet Public Health. janv, vol.4, issue.1, pp.19-27, 2019.

N. Li, S. Franceschi, R. Howell-jones, P. Snijders, and G. M. Clifford, Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication, Int J Cancer. 15 févr, vol.128, issue.4, pp.927-962, 2011.

, National HPV Vaccination Program Register, p.13, 2019.

D. Sur,

, Office of the Prime Minister of Australia. A new vaccine to strengthen the health of young Australians, p.13, 2017.

D. Sur,

. Hpv-vaccine, Human Papillomavirus Vaccine) | Vaccine Knowledge

D. Sur,

P. Health-england, HPV vaccine coverage annual report for, 2017.

D. Sur,

, US Food and Drug Administration. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old, 2018.

D. Sur,

L. D. Oshman and A. M. Davis, Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP), JAMA, vol.4, issue.2020, pp.468-477

M. Drolet, É. Bénard, N. Pérez, M. Brisson, H. Ali et al., Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis, The Lancet. août, vol.394, pp.497-509, 2019.

P. J. Woestenberg, J. A. Bogaards, A. J. King, S. Leussink, S. Ma-van-der et al., Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study, Int J Cancer, vol.144, issue.11, pp.2718-2745, 2019.

T. Palmer, L. Wallace, K. G. Pollock, K. Cuschieri, C. Robertson et al., Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study, BMJ. 3 avr, vol.365, p.1161, 2019.

A. R. Kreimer, F. Struyf, D. Rosario-raymundo, M. R. Hildesheim, A. Skinner et al., Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials, Lancet Oncol. juill, vol.16, issue.7, pp.775-86, 2015.

J. Paavonen, P. Naud, J. Salmerón, C. Wheeler, S. Chow et al., Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women, The Lancet. juill, vol.374, issue.9686, pp.301-315, 2009.

M. Lehtinen and J. Dillner, Clinical trials of human papillomavirus vaccines and beyond, Nat Rev Clin Oncol. juill, vol.10, issue.7, pp.400-410, 2013.

D. R. Brown, S. K. Kjaer, K. Sigurdsson, O. Iversen, M. Hernandez-avila et al., The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years, J Infect Dis. avr, vol.199, issue.7, pp.926-961, 2009.

I. Heard, L. Tondeur, L. Arowas, M. Demazoin, M. Falguières et al., Effectiveness of HPV vaccination on prevalence of vaccine genotypes in young sexually active women in France, J Infect Dis. 23 déc, p.639, 2016.

D. A. Machalek, S. M. Garland, J. Brotherton, D. Bateson, K. Mcnamee et al., Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18-to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination, J Infect Dis. 23 avr, vol.217, issue.10, pp.1590-600, 2018.

E. Chow, D. A. Machalek, S. N. Tabrizi, J. A. Danielewski, G. Fehler et al., Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study, Lancet Infect Dis. janv, vol.17, issue.1, pp.68-77, 2017.

, Australian Institute of Health and Welfare. Cervical screening in Australia, 2018.

, Canberra: AIHW, 2018.

H. Ali, H. Mcmanus, O. Connor, C. C. Callander, D. Kong et al., Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data, Med J Aust. mars, vol.206, issue.5, pp.204-213, 2017.

F. Guo, L. E. Cofie, and A. B. Berenson, Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction, Am J Prev Med. août, vol.55, issue.2, pp.197-204, 2018.

A. A. Cleveland, J. W. Gargano, I. U. Park, M. R. Griffin, L. M. Niccolai et al., Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, Int J Cancer. 1 févr, vol.146, issue.3, pp.810-818, 2008.

S. E. Oliver, E. R. Unger, R. Lewis, D. Mcdaniel, J. W. Gargano et al., Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, J Infect Dis. 1 sept, vol.216, issue.5, pp.594-603, 2003.

M. Steben, T. Thompson, M. Rodier, C. Mallette, N. Racovitan et al., A Review of the Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: 10 Years of Clinical Experience in Canada, J Obstet Gynaecol Can. 1 déc, vol.40, issue.12, pp.1635-1680, 2018.

J. Dillner, M. Nygård, C. Munk, M. Hortlund, B. T. Hansen et al., Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs, Vaccine. juin, vol.36, issue.26, pp.3820-3829, 2018.

B. Feiring, I. Laake, I. K. Christiansen, M. Hansen, J. Stålcrantz et al., Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway, J Infect Dis, vol.218, issue.12, pp.1900-1910, 2018.

D. Mesher, K. Panwar, S. L. Thomas, C. Edmundson, Y. H. Choi et al., The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, J Infect Dis. 14 août, vol.218, issue.6, pp.911-932, 2018.

P. J. Woestenberg, A. J. King, B. Van-benthem, R. Donken, S. Leussink et al., Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors, J Infect Dis. 4 janv, vol.217, issue.2, pp.213-235, 2018.

M. J. Purriños-hermida, M. I. Santiago-pérez, M. Treviño, R. Dopazo, A. Cañizares et al., Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain. Grce M, éditeur. PLOS ONE. 3 août, vol.13, issue.8, p.201653, 2018.

. Insee, Tableaux de l'économie française: Population active

N. Bajos and . Bm, Enquête sur la sexualité en France. Pratiques, genre et santé, pp.324-330, 2010.

V. Goulet, B. De-barbeyrac, S. Raherison, M. Prudhomme, C. Semaille et al., Prevalence of Chlamydia trachomatis: results from the first national population-based survey in France, Sex Transm Infect. 1 août, vol.86, issue.4, pp.263-70, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00557458

, Chiffres du tabac / Vos questions /Nos reponses / Accueil -tabac-info-service.fr

D. Sur,

J. Guthmann, C. Pelat, N. Célant, I. Parent-du-chatelet, N. Duport et al., Socioeconomic inequalities to accessing vaccination against human papillomavirus in France: Results of the Health, Health Care and Insurance Survey, Rev DÉpidémiologie Santé Publique. avr, vol.65, issue.2, pp.109-126, 2012.

A. Bertaut, P. Chavanet, S. Aho, K. Astruc, S. Douvier et al., HPV vaccination coverage in French girls attending middle and high schools: a declarative cross sectional study in the department of Côte d'Or, Eur J Obstet Gynecol Reprod Biol, vol.170, issue.2, pp.526-558, 2013.

N. Muñoz, S. K. Kjaer, K. Sigurdsson, O. Iversen, M. Hernandez-avila et al., Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women, JNCI J Natl Cancer Inst. 3 mars, vol.102, issue.5, pp.325-364, 2010.

M. Lehtinen, J. Paavonen, C. M. Wheeler, U. Jaisamrarn, S. M. Garland et al., Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial, Lancet Oncol. janv, vol.13, issue.1, pp.89-99, 2012.

E. Crowe, N. Pandeya, J. Brotherton, A. J. Dobson, S. Kisely et al., Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: casecontrol study nested within a population based screening programme in Australia, BMJ. 4 mars, vol.348, issue.2, pp.1458-1458, 2014.

K. Pollock, K. Kavanagh, A. Potts, J. Love, K. Cuschieri et al., Reduction of lowand high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland, Br J Cancer, vol.111, issue.9, pp.1824-1854, 2014.

A. M. Rodriguez, B. Zeybek, M. Vaughn, J. Westra, S. Kaul et al., Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study, Cancer, vol.10, issue.2020

D. Sur,

R. Konno, H. Konishi, C. Sauvaget, Y. Ohashi, and T. Kakizoe, Effectiveness of HPV vaccination against high grade cervical lesions in Japan, Vaccine. déc, vol.36, issue.52, pp.7913-7918, 2018.

, Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: Collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies, Int J Cancer, vol.120, issue.4, pp.885-91, 2007.

P. E. Castle, A Prospective Study of High-Grade Cervical Neoplasia Risk Among Human Papillomavirus-Infected Women. CancerSpectrum Knowl Environ, vol.94, pp.1406-1420, 2002.

K. E. Jensen, S. Schmiedel, K. Frederiksen, B. Norrild, T. Iftner et al., Risk for Cervical Intraepithelial Neoplasia Grade 3 or Worse in Relation to Smoking among Women with Persistent Human Papillomavirus Infection, Cancer Epidemiol Biomarkers Prev, vol.21, issue.11, pp.1949-55, 2012.

L. E. Markowitz, A. L. Naleway, R. M. Lewis, B. Crane, T. D. Querec et al., Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination, Vaccine. juin, vol.37, issue.29, pp.3918-3942, 2019.

C. Covert, L. Ding, D. Brown, E. L. Franco, D. I. Bernstein et al., Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction, vol.15, pp.1962-1971, 2019.

S. Mori, S. Nakao, I. Kukimoto, R. Kusumoto-matsuo, K. Kondo et al., Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers, Cancer Sci. juin, vol.102, issue.6, pp.1223-1230, 2011.

J. E. Tota, A. V. Ramanakumar, M. Jiang, J. Dillner, S. D. Walter et al., Epidemiologic Approaches to Evaluating the Potential for Human Papillomavirus Type Replacement Postvaccination, Am J Epidemiol. 15 août, vol.178, issue.4, pp.625-659, 2013.

S. S. Huang, Post-PCV7 Changes in Colonizing Pneumococcal Serotypes in 16 Massachusetts Communities, PEDIATRICS. 1 sept, vol.116, issue.3, pp.408-421, 2001.

B. E. Gonzalez, K. G. Hulten, L. Lamberth, S. L. Kaplan, and E. O. Mason, Streptococcus pneumoniae Serogroups 15 and 33: An Increasing Cause of Pneumococcal Infections in Children in the United States After the Introduction of the Pneumococcal 7-Valent Conjugate Vaccine, Pediatr Infect Dis J. avr, vol.25, issue.4, pp.301-306, 2006.

H. Bernard, Coevolution of papiliomaviruses with human populations, Trends Microbiol. avr, vol.2, issue.4, pp.140-143, 1994.

J. E. Tota, M. Jiang, A. V. Ramanakumar, S. D. Walter, J. S. Kaufman et al.,

, Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination. Meyers C, éditeur, PLOS ONE. 22 déc, vol.11, issue.12, p.166329, 2016.

J. E. Tota, F. Struyf, M. Merikukka, P. Gonzalez, A. R. Kreimer et al., Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials, J Natl Cancer Inst. janv, vol.109, issue.7, p.300, 2017.

P. Gray, J. Palmroth, T. Luostarinen, D. Apter, G. Dubin et al., Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II): Evaluation of HPV type-replacement, Int J Cancer. 15 juin, vol.142, issue.12, pp.2491-500, 2018.

M. Saccucci, E. L. Franco, L. Ding, D. I. Bernstein, D. Brown et al., Non-Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection, Sex Transm Dis. avr, vol.45, issue.4, pp.260-265, 2018.

L. E. Widdice, L. Ding, and J. A. Kahn, Differences between Vaccinated and Unvaccinated Women Explain Increase in Non-Vaccine-Type Human Papillomavirus in Unvaccinated Women after Vaccine Introduction, J Adolesc Health. févr, vol.62, issue.2, p.5, 2018.

P. Goggin, C. Sauvageau, V. Gilca, F. Defay, G. Lambert et al., Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada. Hum Vaccines Immunother. 2 janv, vol.14, issue.1, pp.118-141, 2018.

C. H. Bretagne, V. Jooste, D. Guenat, D. Riethmuller, A. M. Bouvier et al., Prevalence and distribution of HPV genotypes and cervical-associated lesions in sexually active young French women following HPV vaccine, J Gynecol Obstet Hum Reprod. 1 déc, vol.47, issue.10, pp.525-556, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01821665

D. Mesher, K. Soldan, M. Lehtinen, S. Beddows, M. Brisson et al., Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. Emerg Infect Dis, vol.22, pp.1732-1772, 2016.

A. Soderlund-strand, I. Uhnoo, and J. Dillner, Change in Population Prevalences of Human Papillomavirus after Initiation of Vaccination: The High-Throughput HPV Monitoring Study, Cancer Epidemiol Biomarkers Prev. 1 déc, vol.23, issue.12, pp.2757-64, 2014.

L. Ding, L. E. Widdice, and J. A. Kahn, Differences between vaccinated and unvaccinated women explain increase in non-vaccine-type human papillomavirus in unvaccinated women after vaccine introduction, Vaccine. déc, vol.35, issue.52, pp.7217-7238, 2017.

C. Hopenhayn, A. Christian, W. J. Christian, M. Watson, E. R. Unger et al., Prevalence of Human Papillomavirus Types in Invasive Cervical Cancers From 7 US Cancer Registries Before Vaccine Introduction, J Low Genit Tract Dis. avr, vol.18, issue.2, pp.182-191, 2014.

M. Schiffman, G. Clifford, and F. M. Buonaguro, Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline, Infect Agent Cancer. déc, vol.4, issue.1, p.8, 2009.

S. Wu, L. Meng, S. Wang, and D. Ma, A comparison of four screening methods for cervical neoplasia, Int J Gynecol Obstet, vol.91, issue.2, pp.189-93, 2005.

L. S. Massad and Y. C. Collins, Strength of correlations between colposcopic impression and biopsy histology, Gynecol Oncol. 1 juin, vol.89, issue.3, pp.424-432, 2003.

L. M. Niccolai, V. Mcbride, and P. R. Julian, Sources of information for assessing human papillomavirus vaccination history among young women, Vaccine. mai, vol.32, issue.25, pp.2945-2952, 2014.

S. L. Osborne, S. N. Tabrizi, J. Brotherton, A. M. Cornall, J. D. Wark et al., Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program, Vaccine. janv, vol.33, issue.1, pp.201-209, 2015.

M. Arbyn, D. V. Broeck, I. Benoy, J. Bogers, C. Depuydt et al., Surveillance of effects of HPV vaccination in Belgium, Cancer Epidemiol. avr, vol.41, pp.152-160, 2016.

M. Brisson, É. Bénard, M. Drolet, J. A. Bogaards, I. Baussano et al., Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models, Lancet Public Health, vol.1, issue.1, pp.8-17, 2016.

A. Castanon, R. Landy, F. Pesola, P. Windridge, and P. Sasieni, Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study, Lancet Public Health. janv, vol.3, issue.1, pp.34-43, 2018.

K. T. Simms, J. Steinberg, M. Caruana, M. A. Smith, J. Lew et al., Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study, Lancet Oncol. mars, vol.20, issue.3, pp.394-407, 2019.

, Accelerating the elimination of cervical cancer as a global public health problem

K. Canfell, Towards the global elimination of cervical cancer, Papillomavirus Res. déc, vol.8, p.100170, 2019.

M. Brisson, J. J. Kim, K. Canfell, M. Drolet, G. Gingras et al., Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. The Lancet, vol.2020, pp.575-90, 10224.

J. Brotherton, A. Budd, C. Rompotis, N. Bartlett, M. J. Malloy et al., Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis, Papillomavirus Res. déc, vol.8, p.100177, 2019.

R. Sankaranarayanan, S. Joshi, R. Muwonge, P. O. Esmy, P. Basu et al., Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study, Vaccine. août, vol.36, issue.32, pp.4783-91, 2018.

C. Dehlendorff, P. Sparén, B. Baldur-felskov, E. Herweijer, L. Arnheim-dahlström et al., Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions, Vaccine. oct, vol.36, issue.43, pp.6373-6381, 2018.

F. Verdoodt, C. Dehlendorff, and S. K. Kjaer, Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study, Clin Infect Dis. 20 mars, p.239, 2019.

A. R. Kreimer, R. Herrero, J. N. Sampson, C. Porras, D. R. Lowy et al., Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies, Vaccine. août, vol.36, issue.32, pp.4774-82, 2018.

V. Gilca, C. Sauvageau, G. Panicker, D. Serres, G. Schiller et al., Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials, Hum Vaccines Immunother. 3 août, vol.15, issue.7-8, pp.1980-1985, 2019.

K. D. Shield, M. Micallef, C. De-martel, C. Heard, I. Megraud et al., New cancer cases in France in 2015 attributable to infectious agents: a systematic review and meta-analysis

, Eur J Epidemiol. 1 mars, vol.33, issue.3, pp.263-74, 2018.

, Public consultation on draft guidance for introduction of HPV vaccines in EU countries: focus on 9-valent HPV vaccine and vaccination of boys and people living with HIV, Disponible sur

H. W. Chesson, D. U. Ekwueme, M. Saraiya, E. F. Dunne, and L. E. Markowitz, The cost-effectiveness of male HPV vaccination in the United States. Vaccine, vol.29, pp.8443-50, 2011.

S. Datta, J. Pink, G. F. Medley, S. Petrou, S. Staniszewska et al., Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK, BMC Infect Dis. 24 juin, vol.19, issue.1, p.552, 2019.

S. S. Ng, R. Hutubessy, and N. Chaiyakunapruk, Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination, Vaccine. mai, vol.36, issue.19, pp.2529-2573, 2018.

L. E. Markowitz, J. Gee, H. Chesson, and S. Stokley, Ten Years of Human Papillomavirus Vaccination in the United States, Acad Pediatr. mars, vol.18, issue.2, pp.3-10, 2018.

A. M. Rodriguez, T. Do, M. Goodman, K. M. Schmeler, S. Kaul et al., Human Papillomavirus Vaccine Interventions in the U.S.: A Systematic Review and Meta-analysis, Am J Prev Med. avr, vol.56, issue.4, pp.591-602, 2019.

E. A. Smulian, K. R. Mitchell, and S. Stokley, Interventions to increase HPV vaccination coverage: A systematic review, Hum Vaccines Immunother. 2 juin, vol.12, issue.6, pp.1566-88, 2016.

C. Robbins, S. C. Ward, K. Skinner, and S. R. , School-based vaccination: A systematic review of process evaluations, Vaccine. déc, vol.29, issue.52, pp.9588-99, 2011.

K. T. Simms, M. A. Smith, J. Lew, H. C. Kitchener, P. E. Castle et al., Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries: Will cervical screening remain cost-effective, Int J Cancer. 15 déc, vol.139, issue.12, pp.2771-80, 2016.

R. Landy, P. Windridge, M. S. Gillman, and P. D. Sasieni, What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study: Cervical screening in women vaccinated against HPV, Int J Cancer. 15 févr, vol.142, issue.4, pp.709-727, 2018.

F. Santé-publique, Estimations nationales et régionales du nombre de diagnostics d'infections à Chlamydia et à gonocoque en France en 2016, 2018.

D. Sur,

, Après accord, cette demande est transmise au centre coordinateur de la base de données qui réalise les analyses ou met en contact le responsable du projet avec les médecins chargés du suivi médical. Seul votre médecin est habilité à prendre contact avec vous et d'autres patients concernés pour présenter l'étude et proposer d'y participer. L'utilisation des données n'est pas limitée dans le temps. Les résultats des travaux de recherche peuvent être publiés dans les revues scientifiques accessibles dans le monde entier, y compris par internet, afin que les connaissances apportées par ces recherches puissent aider les chercheurs internationaux. A aucun moment vos données personnelles seront identifiables lors de la publication des résultats des travaux de recherche et votre anonymat sera entièrement respecté, Quelle utilisation des données recueillies ? Grâce aux données de toutes les patientes répertoriées dans la base, des études pourront être développées

, Ce document vous appartient et nous vous invitons à en discuter avec votre médecin et/ou avec vos proches. Nous vous remercions de votre participation à cette recherche. Médecin Nom : ???????????????????????????. Prénom : ?????????????????????????. Service du médecin : ??????????????????

, Date information du patient: I__I__I -I__I__I -I__I__I Signature du médecin

J. , oppose pas à l'utilisation des données de mon dossier médical et à être recontacter s'il y a besoin de compléter mon dossier, LSIL) Oui cytologie de haut grade